Overview

Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer

Status:
Not yet recruiting
Trial end date:
2024-12-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect of pyrotinib
Phase:
Phase 2
Details
Lead Sponsor:
Fujian Medical University Union Hospital
Treatments:
Capecitabine